NCH competitors

Daniel is the President and CEO of Interface, Inc. and Chairman of the Board. He joined the Company in 1983 after having worked previously for a national accounting firm. He was promoted to Treasurer of the Company in 1984, Chief Financial Officer in 1985, Vice President-Finance in 1986, Senior Vice President-Finance in 1995, Executive Vice President in 2000, and President and Chief Executive Officer in July 2001. He served as CEO until March 2017, and reassumed the CEO position in January 2020. Mr. Hendrix served as a director of office technology solutions provider Global Imaging Systems, Inc. from 2003 to 2007, and has served as a director of American Woodmark Corporation since May 2005. With more than 30 years of service at the Company, Mr. Hendrix brings to the Board a unique understanding of our strategies and operations. His experience extends to virtually all aspects of the Company’s business, but with a particular emphasis on strategic planning and financial matters. His tenure provides consistent leadership to the Board, and facilitates the interrelationship between the Board and the Company’s executive leadership team.

Chris Hadarits is a Chief Executive Officer at Metro Group Inc.

Transformational and innovative life sciences CEO with a proven track record of growing and turning around businesses with significant value creation. Domain expertise in medical devices, mobile and digital health and pet health. Full-function general management experience in both start-up and established organizations with responsibility from 3 to 500 people. Expert in developing and launching new and complex technologies, building, developing as well as restructuring teams and managing intercultural businesses, including four expatriate assignments on two continents. Fluent in French, German and Italian. OBJECTIVE - CEO of a pre-revenue, growth stage, turnaround, pre-IPO or public company - Operating/consulting partner with VC, PE or Consulting Firm SELECT ACCOMPLISHMENTS • Successfully ran two public companies, Vasomedical, Inc. (NASDAQ) and BioSig Technologies (OTCQB at the time now on NASDAQ) and took BioSig public through a self-filed S1 followed by raising $15 million in private placements. • Conducted two successful turnarounds, Vasomedical and HeartSine Technologies, both nearly out of cash when I joined them. • Introduced several new, complex products at Medtronic, SCIMED, Boston Scientific, US Surgical, Sorin, and HeartSine. • Built or transformed distribution networks at Boston Scientific, US Surgical, Datascope, Sorin and HeartSine Technologies. • Grew business from $94 to $150 million in a year at Boston Scientific and from $29 to $40 million at Sorin (also in 1 year). KEY SKILLS Executive Leadership - Fund Raising - Investor Relations - Strategic Planning & Implementation - General Management - P&L Management - Product Development - Clinical Development - Quality & Regulatory Management - Innovation - Entrepreneurship - Intrepreneurship - Cross Functional Team Leadership - Strategic Partnerships - Mergers and Acquisitions - Team Building - Coaching - Mentoring - Transformational Leadership - Change Management - Product Management - Strategic Marketing - Brand Management - Commercial Strategy - Global Business Development - Market Development - Channel Development - Customer Relationship Building - Medical Devices - Capital Equipment - Digital Health - Mobile Health - Program Management Telephone: 617-286-4997 E-mail: gregorydcash@gmail.com